Ferroptosis-IN-25

Ferroptosis-IN-25 (Compound 20) (24 h) potently inhibits RSL3 (HY-100218A)-induced ferroptosis in HT22 cells with an IC₅₀ of 0.036 μM^[1].
Ferroptosis-IN-25 (24 h) exhibits moderate cytotoxicity in HT22 cells with a TC₅₀ of 45 μM, yielding a high safety index of 1125^[1].
Ferroptosis-IN-25 (30 min) demonstrates potent DPPH radical scavenging activity with an EC₅₀ of 5.4 μM in a cell-free assay^[1].
Ferroptosis-IN-25 has low peroxyl radical quenching capacity with an ORAC value of 0.34 Trolox (HY-101445) equivalents in a cell-free assay^[1].
Ferroptosis-IN-25 (24 h) potently inhibits glutamate-induced oxytosis in HT22 cells with an IC₅₀ of 0.15 μM^[1].
Ferroptosis-IN-25 (0.025-0.2 μM; 8 h) significantly reduces intracellular ROS accumulation in glutamate-treated HT22 cells, without restoring depleted GSH levels^[1].
Ferroptosis-IN-25 (24 h) potently inhibits RSL3-induced ferroptosis in HCECs with an IC₅₀ of 0.052 μM^[1].
Ferroptosis-IN-25 (8 h) significantly inhibits RSL3-induced lipid peroxidation in HCECs^[1].
Ferroptosis-IN-25 (24 h) does not protect HT-29 cells against TSZ-induced necroptosis, demonstrating selective activity for ferroptosis over necroptosis^[1].
Ferroptosis-IN-25 (24 h) does not protect HCECs against STS-induced apoptosis, demonstrating selective activity for ferroptosis over apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.